nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Uveitis—Vemurafenib—melanoma	0.0929	0.127	CcSEcCtD
Metipranolol—Atrial fibrillation—Vemurafenib—melanoma	0.0249	0.034	CcSEcCtD
Metipranolol—Arthritis—Vemurafenib—melanoma	0.0242	0.0331	CcSEcCtD
Metipranolol—Lacrimation—Docetaxel—melanoma	0.0188	0.0257	CcSEcCtD
Metipranolol—Abnormal vision—Carmustine—melanoma	0.015	0.0205	CcSEcCtD
Metipranolol—Arthritis—Bleomycin—melanoma	0.0147	0.0201	CcSEcCtD
Metipranolol—Abnormal vision—Temozolomide—melanoma	0.0145	0.0198	CcSEcCtD
Metipranolol—Cough—Vemurafenib—melanoma	0.0124	0.0169	CcSEcCtD
Metipranolol—Myalgia—Vemurafenib—melanoma	0.0121	0.0165	CcSEcCtD
Metipranolol—Lacrimation increased—Docetaxel—melanoma	0.012	0.0164	CcSEcCtD
Metipranolol—Acute coronary syndrome—Bleomycin—melanoma	0.0108	0.0148	CcSEcCtD
Metipranolol—Myocardial infarction—Bleomycin—melanoma	0.0108	0.0147	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Vemurafenib—melanoma	0.0106	0.0144	CcSEcCtD
Metipranolol—Bronchitis—Temozolomide—melanoma	0.01	0.0137	CcSEcCtD
Metipranolol—Hypersensitivity—Vemurafenib—melanoma	0.00853	0.0117	CcSEcCtD
Metipranolol—Atrial fibrillation—Docetaxel—melanoma	0.00845	0.0116	CcSEcCtD
Metipranolol—Asthenia—Vemurafenib—melanoma	0.00831	0.0114	CcSEcCtD
Metipranolol—Visual impairment—Carmustine—melanoma	0.00831	0.0114	CcSEcCtD
Metipranolol—Visual impairment—Temozolomide—melanoma	0.00803	0.011	CcSEcCtD
Metipranolol—Dizziness—Vemurafenib—melanoma	0.00766	0.0105	CcSEcCtD
Metipranolol—Cough—Bleomycin—melanoma	0.0075	0.0103	CcSEcCtD
Metipranolol—Myalgia—Bleomycin—melanoma	0.00732	0.01	CcSEcCtD
Metipranolol—Rash—Vemurafenib—melanoma	0.0073	0.00998	CcSEcCtD
Metipranolol—Dermatitis—Vemurafenib—melanoma	0.0073	0.00997	CcSEcCtD
Metipranolol—Headache—Vemurafenib—melanoma	0.00726	0.00992	CcSEcCtD
Metipranolol—Discomfort—Bleomycin—melanoma	0.00723	0.00989	CcSEcCtD
Metipranolol—Vision blurred—Carmustine—melanoma	0.00707	0.00967	CcSEcCtD
Metipranolol—Oedema—Bleomycin—melanoma	0.00702	0.00959	CcSEcCtD
Metipranolol—Nausea—Vemurafenib—melanoma	0.00688	0.00941	CcSEcCtD
Metipranolol—Vision blurred—Temozolomide—melanoma	0.00683	0.00934	CcSEcCtD
Metipranolol—Myalgia—Dactinomycin—melanoma	0.00683	0.00933	CcSEcCtD
Metipranolol—Discomfort—Dactinomycin—melanoma	0.00674	0.00922	CcSEcCtD
Metipranolol—Angina pectoris—Docetaxel—melanoma	0.00674	0.00922	CcSEcCtD
Metipranolol—Oedema—Dactinomycin—melanoma	0.00654	0.00895	CcSEcCtD
Metipranolol—Hypertension—Carmustine—melanoma	0.00648	0.00886	CcSEcCtD
Metipranolol—Palpitations—Temozolomide—melanoma	0.00641	0.00876	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Bleomycin—melanoma	0.00639	0.00874	CcSEcCtD
Metipranolol—Myalgia—Carmustine—melanoma	0.00639	0.00874	CcSEcCtD
Metipranolol—Anxiety—Carmustine—melanoma	0.00637	0.00871	CcSEcCtD
Metipranolol—Cough—Temozolomide—melanoma	0.00633	0.00865	CcSEcCtD
Metipranolol—Hypertension—Temozolomide—melanoma	0.00626	0.00856	CcSEcCtD
Metipranolol—Dyspnoea—Bleomycin—melanoma	0.00626	0.00855	CcSEcCtD
Metipranolol—Myalgia—Temozolomide—melanoma	0.00617	0.00844	CcSEcCtD
Metipranolol—Anxiety—Temozolomide—melanoma	0.00615	0.00841	CcSEcCtD
Metipranolol—Oedema—Carmustine—melanoma	0.00612	0.00837	CcSEcCtD
Metipranolol—Discomfort—Temozolomide—melanoma	0.0061	0.00834	CcSEcCtD
Metipranolol—Acute coronary syndrome—Docetaxel—melanoma	0.00608	0.00832	CcSEcCtD
Metipranolol—Myocardial infarction—Docetaxel—melanoma	0.00605	0.00827	CcSEcCtD
Metipranolol—Conjunctivitis—Docetaxel—melanoma	0.006	0.0082	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00596	0.00815	CcSEcCtD
Metipranolol—Oedema—Temozolomide—melanoma	0.00592	0.00809	CcSEcCtD
Metipranolol—Epistaxis—Docetaxel—melanoma	0.00582	0.00796	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Carmustine—melanoma	0.00558	0.00763	CcSEcCtD
Metipranolol—Rhinitis—Docetaxel—melanoma	0.00555	0.00759	CcSEcCtD
Metipranolol—Dyspnoea—Carmustine—melanoma	0.00546	0.00747	CcSEcCtD
Metipranolol—Somnolence—Carmustine—melanoma	0.00544	0.00744	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Temozolomide—melanoma	0.00539	0.00737	CcSEcCtD
Metipranolol—Visual impairment—Docetaxel—melanoma	0.00534	0.0073	CcSEcCtD
Metipranolol—Dyspnoea—Temozolomide—melanoma	0.00528	0.00721	CcSEcCtD
Metipranolol—Somnolence—Temozolomide—melanoma	0.00526	0.00719	CcSEcCtD
Metipranolol—Hypersensitivity—Bleomycin—melanoma	0.00517	0.00707	CcSEcCtD
Metipranolol—Asthenia—Bleomycin—melanoma	0.00503	0.00688	CcSEcCtD
Metipranolol—Hypersensitivity—Dactinomycin—melanoma	0.00482	0.00659	CcSEcCtD
Metipranolol—Asthenia—Dactinomycin—melanoma	0.0047	0.00642	CcSEcCtD
Metipranolol—Hypersensitivity—Carmustine—melanoma	0.00451	0.00617	CcSEcCtD
Metipranolol—Rash—Bleomycin—melanoma	0.00442	0.00605	CcSEcCtD
Metipranolol—Dermatitis—Bleomycin—melanoma	0.00442	0.00604	CcSEcCtD
Metipranolol—Asthenia—Carmustine—melanoma	0.00439	0.00601	CcSEcCtD
Metipranolol—Hypersensitivity—Temozolomide—melanoma	0.00436	0.00596	CcSEcCtD
Metipranolol—Palpitations—Docetaxel—melanoma	0.00426	0.00583	CcSEcCtD
Metipranolol—Asthenia—Temozolomide—melanoma	0.00425	0.00581	CcSEcCtD
Metipranolol—Cough—Docetaxel—melanoma	0.00421	0.00575	CcSEcCtD
Metipranolol—Nausea—Bleomycin—melanoma	0.00417	0.0057	CcSEcCtD
Metipranolol—Hypertension—Docetaxel—melanoma	0.00416	0.00569	CcSEcCtD
Metipranolol—Rash—Dactinomycin—melanoma	0.00413	0.00564	CcSEcCtD
Metipranolol—Myalgia—Docetaxel—melanoma	0.00411	0.00561	CcSEcCtD
Metipranolol—Dizziness—Carmustine—melanoma	0.00405	0.00554	CcSEcCtD
Metipranolol—Oedema—Docetaxel—melanoma	0.00394	0.00538	CcSEcCtD
Metipranolol—Dizziness—Temozolomide—melanoma	0.00391	0.00535	CcSEcCtD
Metipranolol—Nausea—Dactinomycin—melanoma	0.00389	0.00531	CcSEcCtD
Metipranolol—Rash—Carmustine—melanoma	0.00386	0.00528	CcSEcCtD
Metipranolol—Dermatitis—Carmustine—melanoma	0.00386	0.00528	CcSEcCtD
Metipranolol—Headache—Carmustine—melanoma	0.00384	0.00525	CcSEcCtD
Metipranolol—Rash—Temozolomide—melanoma	0.00373	0.0051	CcSEcCtD
Metipranolol—Dermatitis—Temozolomide—melanoma	0.00373	0.0051	CcSEcCtD
Metipranolol—Headache—Temozolomide—melanoma	0.00371	0.00507	CcSEcCtD
Metipranolol—Nausea—Carmustine—melanoma	0.00364	0.00497	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Docetaxel—melanoma	0.00359	0.0049	CcSEcCtD
Metipranolol—Nausea—Temozolomide—melanoma	0.00352	0.00481	CcSEcCtD
Metipranolol—Dyspnoea—Docetaxel—melanoma	0.00351	0.0048	CcSEcCtD
Metipranolol—Somnolence—Docetaxel—melanoma	0.0035	0.00478	CcSEcCtD
Metipranolol—Hypersensitivity—Docetaxel—melanoma	0.0029	0.00397	CcSEcCtD
Metipranolol—Asthenia—Docetaxel—melanoma	0.00282	0.00386	CcSEcCtD
Metipranolol—Dizziness—Docetaxel—melanoma	0.0026	0.00356	CcSEcCtD
Metipranolol—Rash—Docetaxel—melanoma	0.00248	0.00339	CcSEcCtD
Metipranolol—Dermatitis—Docetaxel—melanoma	0.00248	0.00339	CcSEcCtD
Metipranolol—Headache—Docetaxel—melanoma	0.00247	0.00337	CcSEcCtD
Metipranolol—Nausea—Docetaxel—melanoma	0.00234	0.0032	CcSEcCtD
Metipranolol—Atenolol—ABCB1—melanoma	0.00181	0.323	CrCbGaD
Metipranolol—Acebutolol—ABCB1—melanoma	0.00167	0.298	CrCbGaD
Metipranolol—Metoprolol—ABCB1—melanoma	0.00141	0.252	CrCbGaD
Metipranolol—Propranolol—ABCB1—melanoma	0.000713	0.127	CrCbGaD
Metipranolol—ADRB2—Signaling Pathways—GRM3—melanoma	0.000324	0.00123	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GNAQ—melanoma	0.000321	0.00122	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CXCR4—melanoma	0.000317	0.00121	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KISS1—melanoma	0.000314	0.00119	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GNAQ—melanoma	0.000314	0.00119	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GNA11—melanoma	0.000313	0.00119	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GAB2—melanoma	0.000313	0.00119	CbGpPWpGaD
Metipranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000312	0.00119	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KISS1—melanoma	0.000307	0.00117	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GNA11—melanoma	0.000306	0.00116	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GAB2—melanoma	0.000306	0.00116	CbGpPWpGaD
Metipranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000305	0.00116	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SKI—melanoma	0.000304	0.00116	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCR1—melanoma	0.000304	0.00116	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MC1R—melanoma	0.000299	0.00114	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCR1—melanoma	0.000297	0.00113	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SKI—melanoma	0.000297	0.00113	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT3—melanoma	0.000296	0.00112	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CXCR4—melanoma	0.000294	0.00112	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MC1R—melanoma	0.000293	0.00111	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GNAQ—melanoma	0.000291	0.00111	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT3—melanoma	0.000289	0.0011	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CXCR4—melanoma	0.000288	0.00109	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GRM1—melanoma	0.000287	0.00109	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCR7—melanoma	0.000287	0.00109	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GNAQ—melanoma	0.000285	0.00108	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCR7—melanoma	0.000281	0.00107	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GRM1—melanoma	0.000281	0.00107	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SUFU—melanoma	0.00028	0.00106	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SUFU—melanoma	0.000274	0.00104	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT3—melanoma	0.000269	0.00102	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT3—melanoma	0.000263	0.000999	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—BCL2L11—melanoma	0.000261	0.000993	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RHOB—melanoma	0.000261	0.000993	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—BCL2L11—melanoma	0.000255	0.000971	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RHOB—melanoma	0.000255	0.000971	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HDAC6—melanoma	0.000251	0.000954	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—EDN1—melanoma	0.000249	0.000945	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HDAC6—melanoma	0.000245	0.000933	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—EDN1—melanoma	0.000243	0.000924	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CSF2—melanoma	0.000243	0.000924	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCR2—melanoma	0.000238	0.000904	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CXCL8—melanoma	0.000238	0.000904	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CSF2—melanoma	0.000238	0.000904	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RAC2—melanoma	0.000234	0.00089	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PRKCA—melanoma	0.000233	0.000886	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCR2—melanoma	0.000233	0.000885	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CXCL8—melanoma	0.000233	0.000884	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—WNT5A—melanoma	0.00023	0.000876	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFC—melanoma	0.00023	0.000876	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RAC2—melanoma	0.000229	0.00087	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PRKCA—melanoma	0.000228	0.000866	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EDN1—melanoma	0.000226	0.000858	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFC—melanoma	0.000225	0.000857	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—WNT5A—melanoma	0.000225	0.000857	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EDN1—melanoma	0.000221	0.000839	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CSF2—melanoma	0.000221	0.000839	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—RAC1—melanoma	0.000216	0.000821	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CSF2—melanoma	0.000216	0.00082	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PRKCA—melanoma	0.000211	0.000804	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—RAC1—melanoma	0.000211	0.000803	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PRKCA—melanoma	0.000207	0.000787	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAP2K2—melanoma	0.000207	0.000786	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAP2K2—melanoma	0.000202	0.000769	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—F2R—melanoma	0.000202	0.000769	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—F2R—melanoma	0.000198	0.000752	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—RAC1—melanoma	0.000196	0.000746	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDNRB—melanoma	0.000196	0.000745	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—RAC1—melanoma	0.000192	0.000729	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDNRB—melanoma	0.000192	0.000728	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTK2B—melanoma	0.00019	0.000723	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTK2B—melanoma	0.000186	0.000707	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GAB2—melanoma	0.000185	0.000703	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GNA11—melanoma	0.000185	0.000703	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FLT1—melanoma	0.000184	0.0007	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CG—melanoma	0.000182	0.000694	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GAB2—melanoma	0.000181	0.000688	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GNA11—melanoma	0.000181	0.000688	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FLT1—melanoma	0.00018	0.000685	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CG—melanoma	0.000178	0.000678	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FOXO4—melanoma	0.000174	0.000661	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HDAC2—melanoma	0.000174	0.000661	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCR4—melanoma	0.000174	0.000661	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GNAQ—melanoma	0.000172	0.000654	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HDAC2—melanoma	0.00017	0.000647	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCR4—melanoma	0.00017	0.000647	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FOXO4—melanoma	0.00017	0.000647	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GNAQ—melanoma	0.000168	0.00064	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CG—melanoma	0.000166	0.00063	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CG—melanoma	0.000162	0.000616	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SYK—melanoma	0.000162	0.000615	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CD—melanoma	0.00016	0.00061	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ITGAV—melanoma	0.000159	0.000603	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT3—melanoma	0.000159	0.000603	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NGFR—melanoma	0.000159	0.000603	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SYK—melanoma	0.000158	0.000601	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CD—melanoma	0.000157	0.000596	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NGFR—melanoma	0.000155	0.00059	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ITGAV—melanoma	0.000155	0.00059	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT3—melanoma	0.000155	0.00059	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SOCS1—melanoma	0.000147	0.000559	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAP2K1—melanoma	0.000147	0.000557	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—S100B—melanoma	0.000147	0.000557	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CD—melanoma	0.000146	0.000554	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SOCS1—melanoma	0.000144	0.000547	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAP2K1—melanoma	0.000143	0.000545	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—S100B—melanoma	0.000143	0.000545	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CD—melanoma	0.000142	0.000542	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ERBB4—melanoma	0.00014	0.000533	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CB—melanoma	0.00014	0.000531	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN2B—melanoma	0.000139	0.000528	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ERBB4—melanoma	0.000137	0.000521	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CB—melanoma	0.000137	0.00052	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN2B—melanoma	0.000136	0.000517	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CD86—melanoma	0.000134	0.000511	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CXCL8—melanoma	0.000134	0.000511	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDN1—melanoma	0.000133	0.000507	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CD86—melanoma	0.000131	0.0005	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CXCL8—melanoma	0.000131	0.0005	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDN1—melanoma	0.00013	0.000496	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CSF2—melanoma	0.00013	0.000495	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF1—melanoma	0.00013	0.000495	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—IL2—melanoma	0.000128	0.000488	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—E2F1—melanoma	0.000128	0.000485	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CSF2—melanoma	0.000127	0.000485	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF1—melanoma	0.000127	0.000485	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CB—melanoma	0.000127	0.000483	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFRA—melanoma	0.000126	0.00048	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—IL2—melanoma	0.000126	0.000477	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ITGB3—melanoma	0.000125	0.000475	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKCA—melanoma	0.000125	0.000475	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—E2F1—melanoma	0.000125	0.000474	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CB—melanoma	0.000124	0.000472	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFRA—melanoma	0.000123	0.000469	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SPP1—melanoma	0.000123	0.000466	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ITGB3—melanoma	0.000122	0.000465	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKCA—melanoma	0.000122	0.000465	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAP2K2—melanoma	0.000122	0.000464	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CXCL8—melanoma	0.000122	0.000464	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SPP1—melanoma	0.00012	0.000456	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAP2K2—melanoma	0.000119	0.000454	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CXCL8—melanoma	0.000119	0.000454	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL2—melanoma	0.000117	0.000443	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TERT—melanoma	0.000116	0.000442	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RAC1—melanoma	0.000116	0.00044	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL2—melanoma	0.000114	0.000434	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TERT—melanoma	0.000114	0.000432	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RAC1—melanoma	0.000113	0.000431	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HIF1A—melanoma	0.000111	0.000422	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HIF1A—melanoma	0.000109	0.000413	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KDR—melanoma	0.000106	0.000404	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KDR—melanoma	0.000104	0.000395	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FN1—melanoma	0.000102	0.000389	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH1—melanoma	0.0001	0.00038	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FN1—melanoma	0.0001	0.00038	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CD80—melanoma	9.8e-05	0.000373	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH1—melanoma	9.79e-05	0.000372	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CG—melanoma	9.79e-05	0.000372	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APC—melanoma	9.79e-05	0.000372	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KIT—melanoma	9.79e-05	0.000372	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—NRAS—melanoma	9.79e-05	0.000372	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGF—melanoma	9.67e-05	0.000368	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CD80—melanoma	9.59e-05	0.000365	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KIT—melanoma	9.57e-05	0.000364	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APC—melanoma	9.57e-05	0.000364	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CG—melanoma	9.57e-05	0.000364	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—NRAS—melanoma	9.57e-05	0.000364	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGF—melanoma	9.46e-05	0.00036	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAPK3—melanoma	9.37e-05	0.000356	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—BRAF—melanoma	9.2e-05	0.00035	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAPK3—melanoma	9.17e-05	0.000349	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—BRAF—melanoma	9e-05	0.000342	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1—melanoma	8.96e-05	0.000341	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAPK1—melanoma	8.92e-05	0.000339	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EGFR—melanoma	8.92e-05	0.000339	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1—melanoma	8.76e-05	0.000333	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAPK1—melanoma	8.72e-05	0.000332	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EGFR—melanoma	8.72e-05	0.000332	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAP2K1—melanoma	8.66e-05	0.000329	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CD—melanoma	8.6e-05	0.000327	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	8.52e-05	0.000324	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAP2K1—melanoma	8.47e-05	0.000322	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—KRAS—melanoma	8.42e-05	0.00032	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CD—melanoma	8.42e-05	0.00032	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	8.34e-05	0.000317	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—KRAS—melanoma	8.24e-05	0.000313	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF2—melanoma	8.24e-05	0.000313	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF2—melanoma	8.06e-05	0.000306	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	7.74e-05	0.000294	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MDM2—melanoma	7.71e-05	0.000293	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ERBB2—melanoma	7.6e-05	0.000289	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	7.57e-05	0.000288	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MDM2—melanoma	7.54e-05	0.000287	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CB—melanoma	7.5e-05	0.000285	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ERBB2—melanoma	7.43e-05	0.000283	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CB—melanoma	7.33e-05	0.000279	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL8—melanoma	7.21e-05	0.000274	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—HRAS—melanoma	7.16e-05	0.000272	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL8—melanoma	7.05e-05	0.000268	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1B—melanoma	7.04e-05	0.000268	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—HRAS—melanoma	7e-05	0.000266	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT1—melanoma	6.96e-05	0.000265	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASP3—melanoma	6.9e-05	0.000262	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL2—melanoma	6.89e-05	0.000262	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1B—melanoma	6.88e-05	0.000262	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL6—melanoma	6.85e-05	0.000261	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT1—melanoma	6.81e-05	0.000259	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASP3—melanoma	6.75e-05	0.000257	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL2—melanoma	6.74e-05	0.000256	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCND1—melanoma	6.71e-05	0.000255	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL6—melanoma	6.7e-05	0.000255	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CTNNB1—melanoma	6.65e-05	0.000253	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCND1—melanoma	6.57e-05	0.00025	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP9—melanoma	6.52e-05	0.000248	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CTNNB1—melanoma	6.5e-05	0.000247	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1A—melanoma	6.49e-05	0.000247	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTEN—melanoma	6.48e-05	0.000246	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NFKB1—melanoma	6.45e-05	0.000245	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP9—melanoma	6.38e-05	0.000242	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1A—melanoma	6.35e-05	0.000242	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTEN—melanoma	6.34e-05	0.000241	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT1—melanoma	6.32e-05	0.00024	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NFKB1—melanoma	6.31e-05	0.00024	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT1—melanoma	6.18e-05	0.000235	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFA—melanoma	5.85e-05	0.000223	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT3—melanoma	5.79e-05	0.00022	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NRAS—melanoma	5.78e-05	0.00022	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFA—melanoma	5.72e-05	0.000218	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT3—melanoma	5.67e-05	0.000216	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NRAS—melanoma	5.65e-05	0.000215	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK3—melanoma	5.54e-05	0.000211	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK3—melanoma	5.42e-05	0.000206	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MYC—melanoma	5.38e-05	0.000205	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK1—melanoma	5.27e-05	0.0002	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MYC—melanoma	5.27e-05	0.0002	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGFR—melanoma	5.27e-05	0.0002	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK1—melanoma	5.15e-05	0.000196	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGFR—melanoma	5.15e-05	0.000196	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KRAS—melanoma	4.98e-05	0.000189	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KRAS—melanoma	4.87e-05	0.000185	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CA—melanoma	4.57e-05	0.000174	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CA—melanoma	4.47e-05	0.00017	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TP53—melanoma	4.42e-05	0.000168	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TP53—melanoma	4.33e-05	0.000164	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HRAS—melanoma	4.23e-05	0.000161	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HRAS—melanoma	4.14e-05	0.000157	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL6—melanoma	4.05e-05	0.000154	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL6—melanoma	3.96e-05	0.000151	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT1—melanoma	3.73e-05	0.000142	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT1—melanoma	3.65e-05	0.000139	CbGpPWpGaD
